Insider Transactions in Q1 2021 at Vir Biotechnology, Inc. (VIR)
Insider Transaction List (Q1 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 30
2021
|
Arch Venture Partners Ix, LLC > 10% Shareholder |
BUY
Other acquisition or disposition
|
Direct |
4,174
+50.0%
|
-
|
|
Mar 30
2021
|
Arch Venture Partners Ix, LLC > 10% Shareholder |
SELL
Other acquisition or disposition
|
Indirect |
500,000
-1.74%
|
-
|
|
Mar 30
2021
|
Robert Nelsen Director |
BUY
Other acquisition or disposition
|
Direct |
5,989
+50.0%
|
-
|
|
Mar 30
2021
|
Robert Nelsen Director |
SELL
Other acquisition or disposition
|
Indirect |
500,000
-1.74%
|
-
|
|
Mar 29
2021
|
Ann M. Hanly EVP & Chief Technology Officer |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+50.0%
|
-
|
|
Mar 23
2021
|
Herbert Virgin EVP, Research & CSO |
SELL
Open market or private sale
|
Direct |
7,900
-9.62%
|
$418,700
$53.6 P/Share
|
|
Mar 23
2021
|
Herbert Virgin EVP, Research & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
7,900
+8.78%
|
$7,900
$1.53 P/Share
|
|
Mar 10
2021
|
Herbert Virgin EVP, Research & CSO |
SELL
Open market or private sale
|
Direct |
2,340
-3.06%
|
$112,320
$48.0 P/Share
|
|
Mar 10
2021
|
Herbert Virgin EVP, Research & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
2,340
+2.97%
|
$2,340
$1.53 P/Share
|
|
Mar 09
2021
|
Herbert Virgin EVP, Research & CSO |
SELL
Open market or private sale
|
Direct |
5,560
-6.97%
|
$244,640
$44.8 P/Share
|
|
Mar 09
2021
|
Herbert Virgin EVP, Research & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
5,560
+6.52%
|
$5,560
$1.53 P/Share
|
|
Mar 01
2021
|
Jay Parrish Chief Business Officer |
SELL
Open market or private sale
|
Direct |
6,944
-42.85%
|
$437,472
$63.44 P/Share
|
|
Mar 01
2021
|
Jay Parrish Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,944
+18.75%
|
$6,944
$1.53 P/Share
|
|
Feb 23
2021
|
Herbert Virgin EVP, Research & CSO |
SELL
Open market or private sale
|
Direct |
7,900
-9.62%
|
$497,700
$63.74 P/Share
|
|
Feb 23
2021
|
Herbert Virgin EVP, Research & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
18,900
+18.71%
|
$18,900
$1.53 P/Share
|
|
Feb 16
2021
|
George A Scangos Director |
BUY
Grant, award, or other acquisition
|
Direct |
111,000
+2.35%
|
-
|
|
Feb 16
2021
|
Steven J. Rice Chief Administrative Officer |
BUY
Grant, award, or other acquisition
|
Direct |
20,000
+50.0%
|
-
|
|
Feb 16
2021
|
Phillip Pang EVP & Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
32,000
+22.65%
|
-
|
|
Feb 16
2021
|
Phillip Pang EVP & Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+11.46%
|
$0
$0.86 P/Share
|
|
Feb 16
2021
|
Herbert Virgin EVP, Research & CSO |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+32.19%
|
-
|
|
Feb 16
2021
|
Howard Horn CFO |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+10.98%
|
-
|
|
Feb 12
2021
|
Phillip Pang EVP & Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+12.94%
|
$0
$0.86 P/Share
|
|
Feb 09
2021
|
Herbert Virgin EVP, Research & CSO |
SELL
Open market or private sale
|
Direct |
7,900
-19.22%
|
$560,900
$71.16 P/Share
|
|
Feb 09
2021
|
Herbert Virgin EVP, Research & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
7,900
+16.12%
|
$7,900
$1.53 P/Share
|
|
Feb 01
2021
|
Jay Parrish Chief Business Officer |
SELL
Open market or private sale
|
Direct |
6,944
-3.03%
|
$479,136
$69.91 P/Share
|
|
Feb 01
2021
|
Jay Parrish Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,944
+1.5%
|
$6,944
$1.53 P/Share
|
|
Jan 26
2021
|
Herbert Virgin EVP, Research & CSO |
SELL
Open market or private sale
|
Direct |
31,300
-48.53%
|
$1,502,400
$48.17 P/Share
|
|
Jan 26
2021
|
Herbert Virgin EVP, Research & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
31,300
+32.67%
|
$31,300
$1.53 P/Share
|
|
Jan 15
2021
|
Herbert Virgin EVP, Research & CSO |
SELL
Open market or private sale
|
Direct |
10,530
-24.08%
|
$400,140
$38.0 P/Share
|
|
Jan 15
2021
|
Herbert Virgin EVP, Research & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
10,530
+19.41%
|
$10,530
$1.53 P/Share
|
|
Jan 12
2021
|
Herbert Virgin EVP, Research & CSO |
SELL
Open market or private sale
|
Direct |
3,805
-10.28%
|
$110,345
$29.36 P/Share
|
|
Jan 12
2021
|
Herbert Virgin EVP, Research & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
3,805
+9.32%
|
$3,805
$1.53 P/Share
|
|
Jan 04
2021
|
Jay Parrish Chief Business Officer |
SELL
Open market or private sale
|
Direct |
6,945
-3.03%
|
$180,570
$26.32 P/Share
|
|
Jan 04
2021
|
Jay Parrish Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,945
+2.94%
|
$6,945
$1.49 P/Share
|